West Virginia University School of Medicine

Key Hires in CMC/Technical Operations, Business Development, and Finance MALVERN, Pa.--(BUSINESS WIRE)-- Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced expansion of its leadership team with three key industry veterans: Jason Burdette joining as Senior Vice President, CMC and Technical Operations: Armand Girard as Chief Business Officer; and Tamra Adams, and Chief Financial Officer. These appointments come as the Company expands its remit from pure R&D to encompass support of commercialization. "Jason, Armand and Tamra bring a breadth of experience that will be instrumental to Venatorx as we continue to advance our portfolio and maximize the value of our assets," said Christopher J. Burns, Ph.D., President and CEO of Venatorx. "These additions to our senior leadership team are critical to ensure we are prepared for our NDA resubmission and are strategically positioned for continued success." Jason Burdette – Senior Vice President, CMC and Technical Operations – Burdette started at Venatorx in late 2023 and is an experienced leader with more than 30 years in the pharmaceutical industry across process chemistry, formulation and process development, manufacturing, supply chain management, and technical operations. He joined Venatorx from Aimmune/Nestle Health Science where he was a Senior Vice President and Head of Technical Operations. At Aimmune/Nestle Health Science, Burdette was responsible for formulation and process development, analytical development, CMC, manufacturing science and technology, quality control, quality assurance, supply chain, and product distribution. Before this, he was the Senior Vice President of Technical Operations with Paratek Pharmaceuticals and over the years has worked at Eagle Pharmaceuticals, Shire with aaiPharma, Elan Pharmaceuticals, Sandoz, and Mylan Pharmaceuticals. Burdette earned a bachelor's degree in chemistry and an MBA from West Virginia University. Armand Girard – Chief Business Officer – Girard is a seasoned biopharmaceutical executive with multiple product approvals and launches over his 25 years of experience in strategic planning, corporate development, clinical development, and business development. He has extensive partnering experience having completed collaborations, licenses, acquisitions, and spinouts by and between leading pharmaceutical and biotech companies. Girard joined Venatorx from GlycoMimetics where he was the Chief Business Officer. At GlycoMimetics, he was responsible for corporate strategy, partnering, and managing the company's corporate and institutional alliances supporting the development of uproleselan. Previously, he was Vice President, Technical Assessment and Senior Director for Business Development at Shire Pharmaceuticals to build the product pipeline and support Shire's strategic venture arm through investments. He received his undergraduate degree from Lehigh University and an MBA from St Joseph's Haub School of Business Executive Pharmaceutical Marketing Program. Tamra Adams – Chief Financial Officer – Adams has over 25 years of financial management experience. Most recently, she was CFO at Antios Therapeutics, a clinical-stage biopharmaceutical company that was developing innovative therapies to treat and cure HBV. Adams helped lead a $107 million financing and was responsible for IPO readiness, including filing the S-1. Before joining Antios, she founded Accounting Concepts, Inc., a firm that provided CFO, accounting, and financial services to emerging growth companies in the biopharmaceutical and information technology industries. Before that, Adams was the Senior Financial Executive at Silverstorm Technologies and began her career at Ernst & Young, followed by Goldman Sachs. She received her undergraduate degree from the State University of New York at Albany and received her CPA license in New York State. About Venatorx Pharmaceuticals, Inc. Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections. Venatorx’s lead program, cefepime-taniborbactam, is a clinical-stage antibiotic that successfully completed a Phase 3 study in adults with complicated urinary tract infections (cUTI), including pyelonephritis. In October 2022, BARDA awarded a contract of up to $318M for development and procurement of cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections. Venatorx is also developing an oral antibacterial, ceftibuten-ledaborbactam (formerly known as VNRX-7145), for the treatment of cUTI, including pyelonephritis, caused by certain bacteria in adult patients with limited treatment options; this product is completing Phase 1 and will advance directly to a global Phase 3 cUTI clinical trial. For more information about Venatorx and its anti-infectives portfolio, please visit . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical development of Venatorx Pharmaceuticals’ product candidates.

OMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business Officer Oxford, United Kingdom – 15 November 2023 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Melissa Faris as Chief Business Officer, effective immediately. Melissa joins from GSK, where she held the role of Vice President and Head of Immunology Business Development, leading a team responsible for end-to-end business development activities for immunology and infectious diseases. Prior to this she held a number of senior executive business development roles at GSK both on the buy and sell side and brings more than 25 years of experience in the biopharmaceutical industry in drug discovery, development and product commercialization. Melissa first started her career in clinical drug development at GlaxoWellcome in the US where she spent a decade leading and contributing to development programs for Respiratory medicines from Phase 1 through to registration and launch. In addition, she held a number of enterprise leadership roles internal and external to GSK, including, most recently, as a non-executive Board member for Sitryx Therapeutics. Ros Deegan, Chief Executive Officer at OMass Therapeutics, commented: “Melissa’s broad experience in business and clinical development will be an invaluable asset for OMass as we advance our lead candidate toward IND enabling studies and continue to progress our exciting pipeline of immunology programs. In her new role Melissa will be instrumental in ensuring OMass secures high value partnerships and other opportunities to maximize the value of our assets and drug discovery platform, OdyssION™.” Melissa Faris, Chief Business Officer of OMass Therapeutics, added: “I am thrilled to be joining OMass Therapeutics at such an exciting time in the Company’s development. I look forward to working with the leadership team and Board to maximize the value of our proprietary platform and assets.” Melissa holds a Doctorate of Pharmacy from The Ohio State University and a Bachelor’s of Pharmacy from West Virginia University. Following her doctorate, she completed a specialty residency in infectious diseases at the University of North Carolina at Chapel Hill. Caption: OMass CBO, Melissa Faris -ENDS- OMass Therapeutics ICR Consilium Rosamond Deegan, Chief Executive Officer Phone: +44 (0) 1235 527589 Email: ros.deegan@omass.com Sue Charles / Stella Lempidaki / Kumail Waljee Phone: +44 (0)20 3709 5700 Email: omass@consilium-comms.com About OMass Therapeutics OMass Therapeutics is a biotechnology company discovering medicines against highly- validated target ecosystems, such as membrane proteins or intracellular complexes. The company’s unique OdyssION™ technology platform comprises novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry. This allows OMass to interrogate not just the target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. The result is cell-system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, that target solute carriers, complex-bound proteins, and GPCRs. Headquartered in Oxford, UK, OMass has raised over $160M (£129M) from a top-tier international investor syndicate, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital. To learn more, please visit . Follow us on LinkedIn and Twitter.

Award builds on company’s 23-year state partnership to accelerate better health outcomes for Medicaid membersMCLEAN, Va., Nov. 14, 2023 (GLOBE NEWSWIRE) -- West Virginia’s Department of Health and Human Resources (DHHR) has awarded Acentra Health (formerly Kepro), a leading provider of healthcare technology services and solutions, a five-year contract to continue delivering assessment and utilization management services for children and adults enrolled in the state’s Medicaid fee-for-service and waiver programs. The award continues Acentra Health’s 23 years working with DHHR as a vital partner in delivering critical health services that improve well-being and accelerate better health outcomes. “Our teams in West Virginia are passionate about their work and have a deep understanding of the cultural needs and challenges of the populations they serve, owing to their two-plus decades living and working in the state,” said Acentra Health CEO Todd Stottlemyer. “Acentra Health is grateful to West Virginia’s Department of Health and Human Resources for recognizing the value of that experience serving its Medicaid members, and we look forward to continuing our strong partnership.” According to Acentra Health President and COO Meghan Harris, “The new contract continues Acentra Health’s role in developing and managing programs provided through the Bureaus for Social Services, Behavioral Health, and Medical Services and the West Virginia Children’s Health Insurance Program (WVCHIP). In 2018, Acentra Health partnered with the state to design, implement, and oversee its Health Home Care Coordination model, which integrates social services with community-based physical and mental health resources. A study by West Virginia University found that the model’s diabetes service has helped accelerate better health outcomes across the state, reducing monthly emergency room visits by 36% and hospital admissions by 62% for participants, and reducing costs to the state by $187 per participant.” “Effectively managing chronic diseases, like diabetes, is one the ultimate challenges in healthcare today,” said Cindy Beane, Commissioner, West Virginia Bureau for Medical Services. “Our collaboration with Acentra Health has been an important driver in improving the health of our diabetes population, and we look forward to expanding on that success as part of our continued partnership.” Acentra Health’s clinical teams conduct assessments, eligibility determinations, provider reviews, data collection and analysis for prescribed services in behavioral health, medical, the Socially Necessary Services program, and nursing home pre-admission screenings. The teams also manage state Medicaid waiver programs, including the Traumatic Brain Injury Waiver (TBIW), the Aged and Disabled Waiver (ADW), the Children with Serious Emotional Disorders Waiver (CSED) and Intellectual/Developmental Disabilities Waiver (IDDW). About Acentra Health Acentra Health, formed in 2023 by the merger of industry leaders CNSI and Kepro, combines public sector knowledge, clinical expertise, and technological ingenuity to modernize the healthcare experience for state and federal partners and their priority populations. From designing and developing advanced claims, encounter, and provider solutions that drive efficiency and cost savings to delivering clinically focused service models for care management and quality oversight, Acentra Health is accelerating better outcomes. Acentra Health is backed by Carlyle (NASDAQ: CG), a global investment firm. Visit acentra.com. Media Contact: Janice Moore VP, Corporate Communications 703-214-3552